President Trump will continue to get top-of-the-line medical care for COVID-19 now that he's back at the White House, including the final dose of the new antiviral medication, remdesivir
The requirements laid out by the Food and Drug Administration in advice for drugmakers underscore why it's unlikely a vaccine could clear the agency before Election Day.
Some public health experts hope the growing availability of faster, cheaper tests could lead to a new strategy of widespread testing — one that could finally get the pandemic under control.
More than $6 billion in federal funding has been routed through a firm that manages defense contracts, making the agreements subject to less federal scrutiny and transparency.
California will be the first state to create its own line of generic drugs to cope with high drug prices. A new law lets the state outsource manufacturing but control pricing and distribution.
As COVID-19 forced many addiction treatment clinics to scale back, Colorado brought its clinics on wheels to remote, underserved towns and used telehealth to connect patients with addiction doctors.
A cook at a senior center, Matthew Fentress is one of millions of Americans whose skimpy health insurance plans leave them vulnerable to huge out-of-pocket costs when they get sick.
Vaccine maker Novavax is starting a large coronavirus vaccine trial in the U.K. Gregory Glenn, the company's president of research and development, talks with NPR about how vaccines are tested.
Draft documents obtained by NPR show that the federal government is preparing to enforce new data reporting requirements, threatening to withhold vital Medicare funding from noncompliant hospitals.
There's still much that is unknown. But Dr. Denise Jamieson, chair of the Department of Gynecology and Obstetrics at Emory Healthcare, says recent findings "should be somewhat reassuring."
Volunteers getting the shot help determine if a candidate vaccine works. But what with social distancing and masks, scientists must discern if it's the shot or these other measures preventing illness.
Advisers to the Centers for Disease Control and Prevention discussed on Tuesday who will get the first doses of a coronavirus vaccine when it is available.
Over 100,000 people worldwide are taking part in coronavirus vaccine trials. NPR answers common questions, such as why so many people are needed and what it means to say a vaccine works.
A CDC advisory committee is debating this issue Tuesday. Half of U.S. adults could be considered high priority, yet the initial supply is likely to be only enough for 3% to 5% of the population.
